Noninvasive delivery systems for peptides and proteins in osteoporosis therapy: a retroperspective
- PMID: 19640245
- DOI: 10.3109/03639040903059342
Noninvasive delivery systems for peptides and proteins in osteoporosis therapy: a retroperspective
Abstract
Objective: The aim of this review is to provide the reader general and inspiring prospects in various attempts to make noninvasive delivery systems of calcitonin and teriparatide feasible and as convenient as possible.
Background: Calcitonin and teriparatide play an important role in both calcium homeostasis and bone remodelling. Currently calcitonin is available as a subcutaneous injection and as a nasal spray whereas teriparatide is administered subcutaneously. In the past few years, an increasing number of articles about drug delivery systems for calcitonin and teriparatide have been published. These delivery systems have been developed to overcome the inherent barriers for the uptake across the diverse membranes on the various routes for protein and peptide delivery.
Results: Co-administration of permeation enhancers, mucoadhesive agents, viscosity modifying agents, multifunctional polymers, protease inhibitors as well as encapsulation and chemical modification are utilized in order to improve calcitonin and teriparatide absorption after oral, nasal, pulmonal, or buccal administration.
Conclusion: The majority of research groups have been working on the development of formulations based on the encapsulation of molecules in biodegradable and biocompatible polymeric nanoparticles. However these observations are based on data obtained under different experimental conditions. Hence, it is difficult to compare the obtained results in order to draw general conclusions about the most promising characteristics required for oral and nasal formulations for these peptides.
Similar articles
-
[Drug delivery system for the treatment of osteoporosis].Nihon Rinsho. 1998 Mar;56(3):742-7. Nihon Rinsho. 1998. PMID: 9549367 Review. Japanese.
-
Patient experience with a new teriparatide delivery device.Curr Med Res Opin. 2009 Oct;25(10):2413-22. doi: 10.1185/03007990903173074. Curr Med Res Opin. 2009. PMID: 19656016 Clinical Trial.
-
What is new in the treatment of steroid-induced osteoporosis?Semin Cutan Med Surg. 2007 Dec;26(4):203-9. doi: 10.1016/j.sder.2008.03.004. Semin Cutan Med Surg. 2007. PMID: 18395668
-
Teriparatide [human PTH(1-34)]: 2.5 years of experience on the use and safety of the drug for the treatment of osteoporosis.J Bone Miner Res. 2006 Mar;21(3):354-65. doi: 10.1359/JBMR.051023. Epub 2005 Nov 11. J Bone Miner Res. 2006. PMID: 16491282 Review. No abstract available.
-
Two-year changes in bone mineral density and T scores in patients treated at a pharmacist-run teriparatide clinic.Pharmacotherapy. 2007 Jun;27(6):779-88. doi: 10.1592/phco.27.6.779. Pharmacotherapy. 2007. PMID: 17542760 Clinical Trial.
Cited by
-
Respiratory delivered vaccines: Current status and perspectives in rational formulation design.Acta Pharm Sin B. 2024 Dec;14(12):5132-5160. doi: 10.1016/j.apsb.2024.08.026. Epub 2024 Nov 4. Acta Pharm Sin B. 2024. PMID: 39807330 Free PMC article. Review.
-
Repetition of continuous PTH treatments followed by periodic withdrawals exerts anabolic effects on rat bone.J Bone Miner Metab. 2010 Nov;28(6):641-9. doi: 10.1007/s00774-010-0181-4. J Bone Miner Metab. 2010. PMID: 20393760
-
Strategies to Enhance Drug Absorption via Nasal and Pulmonary Routes.Pharmaceutics. 2019 Mar 11;11(3):113. doi: 10.3390/pharmaceutics11030113. Pharmaceutics. 2019. PMID: 30861990 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous